Patents and exclusivity rights currently prevent companies from making a generic Sirturo (bedaquiline) product. After these expire in October 2024, companies may be allowed to make generic versions of the drug. Although bedaquiline is often referred to as the "generic name" for Sirturo, it is simply the active ingredient and not a generic version.
Sirturo™ (bedaquiline) is a prescription medication approved to treat tuberculosis of the lungs in people who do not have other treatment options. It is used in combination with other tuberculosis drugs.
Sirturo is made by Kemwell Pvt., Ltd., for Janssen Therapeutics. It is currently under the protection of patents and exclusivity rights that prevent any generic Sirturo from being manufactured in the United States.
The first patent for Sirturo is set to expire in October 2024. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to delay or shorten this exclusivity period. This includes such things as lawsuits or other patents for new Sirturo uses. Once the patents and exclusivity rights expire, there may be several companies that manufacture a generic Sirturo drug.
No -- bedaquiline is the active ingredient in Sirturo, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.